ArticleApplied microbiology and biotechnology2020
Bacillus coagulans SANK 70258 suppresses Enterobacteriaceae in the microbiota of ulcerative colitis in vitro and enhances butyrogenesis in healthy microbiota.
Article in Applied microbiology and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Bacillus coagulans TBC169 probiotics for intestinal function recovery after gynecological open surgery: a randomized, double-blind, placebo-controlled trial.International journal of clinical pharmacy · 2025Trial
- Trial
- TargetedFrontiers in microbiology · 2026Article
- Modulation of distinct gut microbiota signatures in acute and chronic DSS-colitis by Bawei Huangqin enema in mice.iScience · 2025Article
- Combination of probiotics enhancing butyrogenesis in colonic microbiota model of patients with ulcerative colitis.Applied microbiology and biotechnology · 2025Article
- Secondary Metabolites fromCurrent research in microbial sciences · 2025Review
- Article
- Anticancer Effects ofLife (Basel, Switzerland) · 2024Article
- Progress of research and application ofFrontiers in cellular and infection microbiology · 2024Review
- Exploring the hemicellulolytic properties and safety of Bacillus paralicheniformis as stepping stone in the use of new fibrolytic beneficial microbes.Scientific reports · 2023Article
- Modulation of the Gut Microbiota to Control Antimicrobial Resistance (AMR)-A Narrative Review with a Focus on Faecal Microbiota Transplantation (FMT).Infectious disease reports · 2023Review
- HPLC-MS-MS quantification of short-chain fatty acids actively secreted by probiotic strains.Frontiers in microbiology · 2023Article
- The Effect of Supplementation withVeterinary sciences · 2022Article
- The Potential of Probiotics to Eradicate Gut Carriage of Pathogenic or Antimicrobial-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- The Kobe University Human Intestinal Microbiota Model for gut intervention studies.Applied microbiology and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The aim of this study was to clarify the effect of the spore-forming and lactic acid-producing probiotic strain, Bacillus coagulans SANK 70258, on human colonic microbiota of healthy subjects and ulcerative colitis patients. A model culture system was employed to construct the in vitro human colonic microbiota, to retain the bacterial species richness and simulate the patient's disordered composition, from the fecal inoculum. Bacterial 16S rRNA gene sequencing confirmed that administration of B. coagulans SANK 70258 (at an initial concentration of 4 × 10
Indexed as
Identifiers
32146494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.